Calliditas Therapeutics AB (Calliditas Therapeutics AB) Accounts Payable & Accrued Expense : $36.67 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Accounts Payable & Accrued Expense?

Calliditas Therapeutics AB's quarterly accounts payable & accrued expense increased from Jun. 2023 ($24.10 Mil) to Sep. 2023 ($28.76 Mil) and increased from Sep. 2023 ($28.76 Mil) to Dec. 2023 ($36.67 Mil).

Calliditas Therapeutics AB's annual accounts payable & accrued expense increased from Dec. 2021 ($12.46 Mil) to Dec. 2022 ($28.35 Mil) and increased from Dec. 2022 ($28.35 Mil) to Dec. 2023 ($36.67 Mil).

Calliditas Therapeutics AB Accounts Payable & Accrued Expense Historical Data

The historical data trend for Calliditas Therapeutics AB's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Accounts Payable & Accrued Expense Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

5.00

10.86

12.46

28.35

36.67

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															18.82	28.35	24.10	28.76	36.67

Calliditas Therapeutics AB Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.